hexen-l-yloxy)trimethylsilane, 6651-36-1; (1-cyclopenten-1-yloxy)trimethylsilane, 19980-43-9; trimethyl[ (1 -phenylethenyl)oxy ]silane, 13735-81-4; l,l'-[[l,2-bis(methylene)-l,2-ethanediyl]bis(oxy)bis(trimethyl)silane, 31411-71-9; trimethyl[ [(1 -phenylmethyl)etheny 1]oxy]silane, 59021-31-7; trimethyl[(1-methyl-2-phenylethenyl)oxy]silane, 43108-63-0; trimethyl[(6-methyl-l-cyclohexen-l-yl)oxy]silane, 19980-33-7; trimethyl[(2-methyl-l-cyclohexen-l-yl)oxy]silane,

The replacement of various functional groups with oxygenated moieties is of considerable importance in synthetic endeavors and has led, over the years, to the development of several reagents that serve as nucleophilic sources of oxygen, including hydroxide,1 peracids,2 su-(1) See:

No abstract

No abstract

No abstract

No abstract

A number of prostaglandins and mono-hydroxylated fatty acids were investigated as substrates for NAD-dependent 15-prostaglandin dehydrogenase (15-PGDH) obtained from human HL-60 cells. Lipoxygenase and cyclooxygenase-derived substrates possessing an w-6 hydroxyl moiety (15-HETE, 13-HODD and HHT) were metabolized to corresponding keto derivatives at a rate comparable to that for prostaglandins E2 and F2 alpha. 12-HETE was a poor substrate and 5-HETE was not metabolized. The w-6 hydroxy fatty acids inhibited the metabolism of PGE2 and therefore they may play a role in modulating bioactive prostaglandin levels.

No abstract